Plantar Fasciitis Treatment growing at a CAGR of 11.9% from 2025 to 2033

Key Market Trends & Insights

• The North America plantar fasciitis treatment market held the largest revenue share of 42.7% in 2024.
• In 2024, the U.S. market led North America with the largest revenue share of 89.5%.
• By drug class, the nonsteroidal anti-inflammatory drugs (NSAIDs) segment accounted for the largest revenue share of 58.7% in 2024.
• By disease type, the acute plantar fasciitis segment held the largest revenue share of 61.5% in 2024.
• By end use, the hospitals & clinics segment dominated the market with the largest revenue share of 60.4% in 2024.

Market Size & Forecast

• 2024 Market Size: USD 1.28 Billion
• 2033 Projected Market Size: USD 3.45 Billion
• CAGR (2025-2033): 7.2%
• North America: Largest market in 2024
• Asia-Pacific: Fastest growing market

Request Free Sample Report: https://www.grandviewresearch.com/industry-analysis/plantar-fasciitis-treatment-market-report/request/rs1

Increasing awareness among patients about foot health, better access to specialized care, and the adoption of advanced treatment options are further supporting market expansion. Hospitals, clinics, and outpatient facilities are emphasizing early diagnosis and effective management of foot-related conditions. Combined, these factors are fueling demand for therapeutic interventions, driving consistent growth and encouraging innovation within the heel and foot care segment.

Although governments rarely provide exact global case figures, estimates suggest that approximately 1 million patient visits yearly are due to plantar fasciitis. Research indicates that around 10% of the population experience plantar fasciitis at some point, with 83% of affected individuals being active working adults aged 25 to 65. Some studies report prevalence rates as high as 22% among runners.

Developments in image-guided interventions, ultrasound-guided injections, and minimally invasive mechanical or sonic therapies improve targeting, reduce recovery time, and enhance efficacy, thus increasing physician and patient adoption. In July 2025, a study published in the American Journal of Physical Medicine & Rehabilitation compared the efficacy of platelet-rich plasma (PRP) and corticosteroids in treating plantar fasciitis. The results indicated that PRP provided superior pain relief and improved foot function over corticosteroid injections. In addition, in July 2025, a study by King George’s Medical University researchers in Lucknow explored the effectiveness of ultrasound-guided dextrose prolotherapy versus PRP injections for chronic heel pain. The study found that both treatments significantly reduced pain and improved foot function, with PRP demonstrating slightly superior outcomes.

Market Concentration & Characteristics

The plantar fasciitis treatment market demonstrates moderate innovation, driven by the development of advanced orthotic devices, minimally invasive procedures, and targeted pharmacological therapies. Companies are investing in research to improve pain relief, enhance healing, and reduce recurrence. Innovations in shockwave therapy, corticosteroid injections, and customized insoles improve patient compliance and outcomes. Continuous innovation helps market players differentiate offerings and strengthen market presence.

High R&D costs, clinical validation requirements, and regulatory approvals create significant entry barriers. Established brand loyalty for orthotics, devices, and pharmaceutical solutions poses challenges for new entrants. Intellectual property protections limit generic and alternative product offerings, maintaining moderate market concentration.

Plantar Fasciitis Treatment Market Report Scope